{"id":"valdecoxib","rwe":[],"tags":[{"label":"valdecoxib","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Prostaglandin G/H synthase 2","category":"target"},{"label":"PTGS2","category":"gene"},{"label":"CA12","category":"gene"},{"label":"CA9","category":"gene"},{"label":"M01AH03","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Acute postoperative pain","category":"indication"},{"label":"Approved 2000s","category":"decade"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Cyclooxygenase 2 Inhibitors","category":"pharmacology"},{"label":"Cyclooxygenase Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":249.186,"date":"","count":75,"signal":"Drug hypersensitivity","source":"DrugCentral FAERS","actionTaken":"Reported 75 times (LLR=249)"}],"drugInteractions":[{"url":"/drug/fluconazole","drug":"fluconazole","action":"Monitor closely","effect":"May interact with Fluconazole","source":"DrugCentral","drugSlug":"fluconazole"},{"url":"/drug/voriconazole","drug":"voriconazole","action":"Monitor closely","effect":"May interact with Voriconazole","source":"DrugCentral","drugSlug":"voriconazole"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=VALDECOXIB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:13:50.187719+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:13:56.009565+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VALDECOXIB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:13:56.327555+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Cyclooxygenase-2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:13:57.542004+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL865/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:13:57.065840+00:00"}},"allNames":"valecoxib","offLabel":[],"synonyms":["valdecoxib","valecoxib"],"timeline":[{"date":"2001-11-16","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Valecoxib, also known as Valdecoxib, is a small molecule drug that targets Prostaglandin G/H synthase 2, a key enzyme involved in pain and inflammation. Originally developed by Pharmacia, it is now owned by Pfizer. It was FDA approved in 2001 for the treatment of acute postoperative pain. Valecoxib is off-patent and has no active generic manufacturers. It has a half-life of 7.4 hours and bioavailability of 83%.","approvals":[{"date":"2001-11-16","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Valecoxib","ecosystem":[{"indication":"Acute postoperative pain","otherDrugs":[{"name":"buprenorphine","slug":"buprenorphine","company":"Reckitt Benckiser"},{"name":"celecoxib","slug":"celecoxib","company":"Gd Searle"},{"name":"fentanyl","slug":"fentanyl","company":"Akorn"},{"name":"hydromorphone","slug":"hydromorphone","company":"Purdue Pharm Prods"}],"globalPrevalence":null}],"mechanism":{"target":"Prostaglandin G/H synthase 2","novelty":"Follow-on","targets":[{"gene":"PTGS2","source":"DrugCentral","target":"Prostaglandin G/H synthase 2","protein":"Prostaglandin G/H synthase 2"},{"gene":"CA12","source":"DrugCentral","target":"Carbonic anhydrase 12","protein":"Carbonic anhydrase 12"},{"gene":"CA9","source":"DrugCentral","target":"Carbonic anhydrase 9","protein":"Carbonic anhydrase 9"},{"gene":"CA2","source":"DrugCentral","target":"Carbonic anhydrase 2","protein":"Carbonic anhydrase 2"},{"gene":"CA5B","source":"DrugCentral","target":"Carbonic anhydrase 5B, mitochondrial","protein":"Carbonic anhydrase 5B, mitochondrial"},{"gene":"CA14","source":"DrugCentral","target":"Carbonic anhydrase 14","protein":"Carbonic anhydrase 14"},{"gene":"CA13","source":"DrugCentral","target":"Carbonic anhydrase 13","protein":"Carbonic anhydrase 13"},{"gene":"CA6","source":"DrugCentral","target":"Carbonic anhydrase 6","protein":"Carbonic anhydrase 6"},{"gene":"CA5A","source":"DrugCentral","target":"Carbonic anhydrase 5A, mitochondrial","protein":"Carbonic anhydrase 5A, mitochondrial"},{"gene":"MT-CO2","source":"DrugCentral","target":"Cytochrome c oxidase subunit 2","protein":"Cytochrome c oxidase subunit 2"}],"modality":"Small Molecule","drugClass":"valdecoxib","explanation":"","oneSentence":"","technicalDetail":"Valecoxib is a non-selective COX-2 inhibitor that blocks the activity of Prostaglandin G/H synthase 2, thereby reducing the production of prostaglandins and subsequent pain and inflammation."},"commercial":{"launchDate":"2001","_launchSource":"DrugCentral (FDA 2001-11-16, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2799","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=VALDECOXIB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VALDECOXIB","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T16:12:11.178771","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:13:58.900008+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rofecoxib","drugSlug":"rofecoxib","fdaApproval":"1999-05-20","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"valdecoxib","indications":{"approved":[{"name":"Acute postoperative pain","source":"DrugCentral","snomedId":107401000119105,"regulator":"FDA"}],"offLabel":[{"name":"Dysmenorrhea","source":"DrugCentral","drugName":"VALDECOXIB"},{"name":"Osteoarthritis","source":"DrugCentral","drugName":"VALDECOXIB"},{"name":"Rheumatoid arthritis","source":"DrugCentral","drugName":"VALDECOXIB","evidenceCount":58,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"},{"drugId":"rofecoxib","brandName":"rofecoxib","genericName":"rofecoxib","approvalYear":"1999","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03915561","phase":"PHASE2","title":"Effect of Intravenous Dynastat on Postoperative Sore Throat","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2019-03-01","conditions":["Sore Throat","Postoperative Complications"],"enrollment":140,"completionDate":"2020-11-30"},{"nctId":"NCT00650624","phase":"PHASE2","title":"A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-06","conditions":["Osteoarthritis, Knee"],"enrollment":416,"completionDate":"2004-01"},{"nctId":"NCT00648258","phase":"PHASE3","title":"A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-07","conditions":["Osteoarthritis"],"enrollment":130,"completionDate":"2004-04"},{"nctId":"NCT00653354","phase":"PHASE3","title":"Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-12","conditions":["Pain, Post-surgical"],"enrollment":360,"completionDate":"2003-03"},{"nctId":"NCT00649415","phase":"PHASE4","title":"A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":["Dysmenorrhea"],"enrollment":154,"completionDate":"2003-07"},{"nctId":"NCT00657449","phase":"PHASE4","title":"A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain","status":"TERMINATED","sponsor":"Pfizer","startDate":"2003-06-04","conditions":["Acute Pain"],"enrollment":45,"completionDate":"2004-10-05"},{"nctId":"NCT00260325","phase":"PHASE4","title":"Effect of Valdecoxib Pretreatment on Pain and Secondary Hyperalgesia in Healthy Volunteers","status":"COMPLETED","sponsor":"Penn State University","startDate":"2004-08","conditions":["Pain","Hyperalgesia"],"enrollment":20,"completionDate":"2006-04"},{"nctId":"NCT00285649","phase":"NA","title":"Predicting Patients' Response to Spinal Manipulation","status":"COMPLETED","sponsor":"Palmer College of Chiropractic","startDate":"2004-07","conditions":["Low Back Pain"],"enrollment":192,"completionDate":"2007-03"},{"nctId":"NCT00115752","phase":"PHASE2","title":"Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain","status":"COMPLETED","sponsor":"National Institute of Nursing Research (NINR)","startDate":"2005-06-20","conditions":["Pain"],"enrollment":96,"completionDate":"2006-10-04"},{"nctId":"NCT00092339","phase":"PHASE3","title":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-08-01","conditions":["Postoperative Pain"],"enrollment":125,"completionDate":"2002-09-15"},{"nctId":"NCT00602901","phase":"PHASE2","title":"Elderly Back Pain: Comparing Chiropractic to Medical Care","status":"COMPLETED","sponsor":"Palmer College of Chiropractic","startDate":"2004-07","conditions":["Subacute Low Back Pain","Chronic Low Back Pain"],"enrollment":240,"completionDate":"2007-03"},{"nctId":"NCT00092300","phase":"PHASE3","title":"A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-05","conditions":["Postoperative Pain"],"enrollment":450,"completionDate":""},{"nctId":"NCT00021996","phase":"NA","title":"Valdecoxib in Treating Chronic Pain in Cancer Patients","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2001-01","conditions":["Pain","Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":0,"completionDate":"2004-02"},{"nctId":"NCT01541137","phase":"NA","title":"NSAIDs With Morphine-PCA Compared to Epidural Analgesia in Thoracotomy Pain","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2004-03","conditions":["Postoperative Pain"],"enrollment":30,"completionDate":"2008-09"},{"nctId":"NCT01361789","phase":"PHASE4","title":"COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined","status":"COMPLETED","sponsor":"Asker & Baerum Hospital","startDate":"2004-01","conditions":["Rupture of Anterior Cruciate Ligament"],"enrollment":93,"completionDate":"2009-12"},{"nctId":"NCT01221025","phase":"PHASE4","title":"Effect Study of Parecoxib to Treat Emergence Delirium and Postoperative Pain","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2010-09","conditions":["Emergence Delirium","Postoperative Pain"],"enrollment":900,"completionDate":"2012-06"},{"nctId":"NCT00651300","phase":"PHASE3","title":"A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery","status":"TERMINATED","sponsor":"Pfizer","startDate":"2003-04","conditions":["Pain"],"enrollment":91,"completionDate":"2004-03"},{"nctId":"NCT00419549","phase":"PHASE2,PHASE3","title":"Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)","status":"TERMINATED","sponsor":"All India Institute of Medical Sciences","startDate":"2003-10","conditions":["ERCP","Pancreatitis"],"enrollment":371,"completionDate":"2005-09"},{"nctId":"NCT00636064","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":["Pain"],"enrollment":1671,"completionDate":"2004-01"},{"nctId":"NCT00650598","phase":"PHASE4","title":"A Multicentre, Double-Blind, Double-Dummy, Randomised Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Diclofenac Sodium in Patients Undergoing Knee Arthroscopy for Anterior Cruciate Ligament (ACL) Reconstruction","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-03","conditions":["Pain, Postoperative"],"enrollment":328,"completionDate":"2004-08"},{"nctId":"NCT00763997","phase":"NA","title":"Study of the Effect of Dipyrone, Ibuprofen, Paracetamol and Parecoxib on the Platelet Aggregation in Analgetic Dosages","status":"COMPLETED","sponsor":"Ruhr University of Bochum","startDate":"2004-02","conditions":["Platelet Aggregation"],"enrollment":80,"completionDate":"2004-12"},{"nctId":"NCT00122096","phase":"PHASE4","title":"Perioperative Inflammation and Cyclooxygenase 2 (COX-2)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2002-11","conditions":["Neurosurgery","Pain"],"enrollment":30,"completionDate":"2006-01"},{"nctId":"NCT00650455","phase":"PHASE4","title":"Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-02","conditions":["Arthritis, Rheumatoid"],"enrollment":489,"completionDate":"2005-01"},{"nctId":"NCT00650039","phase":"PHASE3","title":"Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-03","conditions":["Pain"],"enrollment":488,"completionDate":"2005-02"},{"nctId":"NCT00683137","phase":"PHASE3","title":"Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-10","conditions":["Pain","Hallux Valgus"],"enrollment":450,"completionDate":"2003-02"},{"nctId":"NCT00671320","phase":"PHASE4","title":"A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-12","conditions":["Pain","Sprains and Strains","Sprain"],"enrollment":202,"completionDate":"2003-10"},{"nctId":"NCT00647829","phase":"PHASE3","title":"A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-02","conditions":["Pharyngitis"],"enrollment":197,"completionDate":"2003-12"},{"nctId":"NCT00661635","phase":"PHASE3","title":"A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-11","conditions":["Laparoscopic Cholecystectomy","Pain"],"enrollment":490,"completionDate":"2003-07"},{"nctId":"NCT00660855","phase":"PHASE4","title":"A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib/Valdecoxib 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain","status":"TERMINATED","sponsor":"Pfizer","startDate":"2004-06","conditions":["Pain, Post Surgical"],"enrollment":4,"completionDate":"2004-07"},{"nctId":"NCT00649610","phase":"PHASE4","title":"Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-11","conditions":["Low Back Pain"],"enrollment":340,"completionDate":"2003-05"},{"nctId":"NCT00652808","phase":"PHASE3","title":"Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-05","conditions":["Osteoarthritis","Knee"],"enrollment":265,"completionDate":"2004-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000148721","MMSL":"16210","NDDF":"009503","UNII":"2919279Q3W","VUID":"4021284","CHEBI":"CHEBI:63634","VANDF":"4021284","INN_ID":"7815","RXNORM":"278567","UMLSCUI":"C0913246","chemblId":"CHEMBL865","ChEMBL_ID":"CHEMBL865","KEGG_DRUG":"D02709","DRUGBANK_ID":"DB00580","PDB_CHEM_ID":" COX","PUBCHEM_CID":"119607","SNOMEDCT_US":"385583007","IUPHAR_LIGAND_ID":"2894","MESH_SUPPLEMENTAL_RECORD_UI":"C406224"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"7.4 hours","clearance":"1.4 mL/min/kg","bioavailability":"83%","fractionUnbound":"0.02%","volumeOfDistribution":"0.75 L/kg"},"publicationCount":518,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"M01AH03","allCodes":["M01AH03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2001","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-11-16T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":null,"brand_name_local":"Bextra","application_number":"EMEA/H/C/000431"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Bextra","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:13:58.900008+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}